简介：　　【摘要】目的：分析双黄连注射剂对急性上呼吸道感染（ AURI）的疗效情况。方法： 2017年 1月 -2018年 9月选取我院 86例 AURI患者，按照患者治疗方法不同，将其分为对照组（应用利巴韦林） 43例及观察组（应用双黄连注射剂） 43例，比较两组临床疗效及副反应发生率。结果：观察组临床总有效率为 95.35%，明显高于对照组 81.40%（ P<0.05）。两组副反应发生率对比， P>0.05，差异无统计学意义。结论：采用双黄连注射剂治疗 AURI具有安全性佳、疗效好等优点。  　　【关键词】双黄连注射剂； AURI；疗效；分析  [Abstract] Objective: to analyze the therapeutic effect of Shuanghuanglian Injection on acute upper respiratory tract infection (AURI). Methods: from January 2017 to September 2018, 86 cases of AURI in our hospital were selected. According to different treatment methods, they were divided into control group (ribavirin) 43 cases and observation group (Shuanghuanglian injection) 43 cases. The clinical efficacy and incidence of side effects of the two groups were compared. Results: the total clinical effective rate of the observation group was 95.35%, which was significantly higher than that of the control group (81.40%) (P < 0.05). There was no significant difference between the two groups (P > 0.05). Conclusion: Shuanghuanglian injection is safe and effective in the treatment of AURI.

简介：(武汉市结核病防治所湖北武汉430030)摘要目的观察胸腔内注入肝素治疗结核性包裹性胸膜炎的疗效。方法69例结核性包裹性胸膜炎患者随机分为治疗组（35例）与对照组（34例）。治疗组每次充分引流后注射肝素6250U+生理盐水20ml，对照组不注药。两组抗结核方案均为2HREZ/4HR。结果治疗组显效率34.3%，对照组为8.8%，两者有显著性差异（P﹤0.01）。治疗组总有效率91.4%，对照组为79.4%，两者有显著性差异(P﹤0.01)。治疗2月后，B超观察治疗组胸膜厚度3.8±1.3mm，对照组为6.5±2.9mm，两者有显著性差异（P﹤0.01）。治疗组肺功能FVC％为（89.8±1.7）%，对照组（76.5±1.6）%（P﹤0.05）；治疗组FEV1/FVC%为（85.2±2.9）%，对照组为（74.6±2.5）%，两者差异亦有显著性（P﹤0.05）。结论胸腔内注射肝素能减少胸膜肥厚粘连，改善肺功能，药物安全性好，是一项有效的辅助治疗措施。